91��ý

Harwell Oxford, November 17, 2025, 91��ý (MitoRx), a biotech company developing novel classes of mitochondrial-targeted agents targeting obesity, today announces a GBP 5.5 million (USD 7.2 million) pre-Series A fundraise.

��

The investment will be used to progress development of MitoRx’s lead mitochondrial-targeted��program, Myo-004, through clinical candidate selection. Myo-004 is a first-in-class injectable small molecule��designed to achieve weight loss, without loss of lean mass. The funding will also support an on-going oral program within MitoRx’s Candidate Engine, a platform for the generation and profiling of additional candidates.

��

The pre-Series A financing was led by Oshen Holdings SA (Luxembourg)with significant participation from existing investors. This fundraise follows a recent series of compelling preclinical data presented at leading conferences throughout 2025. ��Data presented at the 32nd European Conference on Obesity, showed that Myo-004 monotherapy drives fat loss while preserving lean mass. When combined with semaglutide, Myo-004 further enhanced fat loss while preserving lean mass [1]. At the American Diabetes Association’s 2025 Scientific Sessions, results were presented that demonstrate that Myo-004 restored insulin sensitivity in an industry-standard murine diet-induced obesity model [2]. Additional data presented at European Association for the Study of Diabetes annual meeting highlight Myo-004’s role in muscle preservation and liver-fat clearance in obesity. The preclinical data findings also revealed increased muscle fiber size in diet-induced obesity cohorts treated withMyo-004, confirming lean mass gains observed via MRI analysis [3].

��

“This MitoRx fundraise clearly shows investors understand that protection of lean mass including muscle is key to therapeutic weight loss. Our small molecules drive fat loss while preserving lean mass through a unique mechanism of action, said Jon Rees, CEO and Co-founder, 91��ý. “This Pre-Series A fundraise will enable MitoRx to complete a comprehensive data package demonstrating that its novel mitochondrial-targeted agents are efficacious, safe and well tolerated solutions for people living with obesity, driving a better quality of weight loss than GLP-1receptor agonists.”

“Obesity has reached unprecedented levels, affecting close to 900 million people worldwide and continuing to rise exponentially,” said Justin Cahill, Managing Partner of Oshen Holdings SA. “While GLP-1 therapies have marked an important step forward, emerging data make it clear they are not the long-term answer. People living with obesity need next-generation solutions that deliver sustainable weight control with fewer side-effects and broader metabolic benefits. MitoRx’s compelling preclinical data package positions it at the forefront of this next wave of innovation. The company’s approach demonstrates meaningful reductions in body and liver fat while preserving muscle mass and insulin sensitivity - key differentiators from current standard treatments. We are delighted to back MitoRx in its mission to develop a truly differentiated, long-term therapeutic solution to address the escalating global obesity crisis.”

As part of the financing, Didier Cowling, Managing Partner of Oshen Holdings SA, has joined MitoRx's Board of Directors, strengthening the company’s strategic leadership as it advances its promising therapies.